Adherence to and Reasons for Premature Discontinuation From Stop-Smoking Medications: Data From the ITC Four-Country Survey

Grants

Funding Acknowledgements

This work was supported by National Health and Medical Research Council of Australia (grant numbers 265903 and 450110), Cancer Research UK (grant number C312/A6465), U.S. National Cancer Institute (grant numbers RO1 CA100362, P50 CA111236, and P01 CA138389), and Canadian Institutes of Health Research (grant number 79551).James Balmford is currently employed part time, through the University of Freiburg, Germany, on a project funded by a Pfizer Global Health Partnership. This work is unrelated to this paper, which is part of his other employment at The Cancer Council Victoria. K. Michael Cummings is employed fulltime at Roswell Park Cancer Institute where he is involved in doing a stop-smoking study supported by Nabi Biopharmaceuticals; he also serves as a paid expert witness on behalf of plaintiffs in litigation against the tobacco industry.